News Article

Isomorphic Labs, the London based artificial intelligence specialist spun out of Google DeepMind, has secured $2.1bn billion dollars in a Series B funding round to accelerate its work on drug discovery.

This capital injection marks a significant milestone for the drug design sector and highlights growing investor confidence in the application of generative AI within the life sciences and healthcare industries.

The financing round was led by Thrive Capital and saw participation from existing backers Alphabet and GV, alongside a diverse group of new international investors including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This latest investment follows a $600m raise in early 2025 and brings the total capital raised by the company to over $2.7bn since its launch in 2021.

The new capital will be used to scale the company’s proprietary AI drug design engine, known as IsoDDE, and to progress its internal pipeline of therapeutic candidates toward clinical development. Isomorphic Labs intends to transition from pioneering novel AI models to applying them at scale across multiple therapeutic areas and drug modalities, with a particular focus on oncology and immunology.

The firm recently reported that its IsoDDE system more than doubled the accuracy of breakthrough artificial intelligence model AlphaFold 3 on certain protein ligand prediction benchmarks, providing the predictive fidelity required to navigate complex biological systems. This technical advancement is crucial for investors and operators as it addresses the long standing challenges of protein structure prediction and molecular interaction in the body.

Strategically, the funding supports the company’s global expansion and hiring targets for world class talent in engineering, drug design, and clinical development across its sites in London, Lausanne, and Cambridge, Massachusetts. Sir Demis Hassabis, the founder and chief executive officer of Isomorphic Labs, described the funding as a massive vote of confidence in the company’s AI first approach to solving disease.

While the firm maintains multibillion dollar partnerships with industry leaders such as Novartis, Eli Lilly, and Johnson & Johnson, it is also advancing its own wholly owned programs. The company expects to enter its first preclinical trials by the end of 2026, marking a pivotal step toward validating its technology in a real-world clinical setting.